Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLL

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This study aims to evaluate the safety, efficacy and duration of response of anti-CD19 anti-CD20 Bispecific Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ and CD20+ haematological malignancies.
Epistemonikos ID: 79b5477b71ebb77af08f335bf67b32fc5dd15615
First added on: May 21, 2024